1. Home
  2. SUNS vs VRCA Comparison

SUNS vs VRCA Comparison

Compare SUNS & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sunrise Realty Trust Inc.

SUNS

Sunrise Realty Trust Inc.

SELL

Current Price

$6.46

Market Cap

108.7M

Sector

Real Estate

ML Signal

SELL

Logo Verrica Pharmaceuticals Inc.

VRCA

Verrica Pharmaceuticals Inc.

HOLD

Current Price

$3.78

Market Cap

88.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SUNS
VRCA
Founded
2023
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
108.7M
88.0M
IPO Year
2024
2018

Fundamental Metrics

Financial Performance
Metric
SUNS
VRCA
Price
$6.46
$3.78
Analyst Decision
Buy
Strong Buy
Analyst Count
4
7
Target Price
$10.50
★ $13.83
AVG Volume (30 Days)
★ 102.1K
44.6K
Earning Date
11-12-2026
11-13-2026
Dividend Yield
★ 18.90%
N/A
EPS Growth
★ N/A
N/A
EPS
★ 0.54
N/A
Revenue
$21,571,434.00
★ $35,577,000.00
Revenue This Year
$89.71
N/A
Revenue Next Year
$11.95
$58.01
P/E Ratio
$11.76
★ N/A
Revenue Growth
102.96
★ 370.22
52 Week Low
$5.77
$3.28
52 Week High
$10.45
$9.82

Technical Indicators

Market Signals
Indicator
SUNS
VRCA
Relative Strength Index (RSI) 44.81 35.23
Support Level $5.77 N/A
Resistance Level $7.90 $5.94
Average True Range (ATR) 0.29 0.35
MACD 0.03 -0.05
Stochastic Oscillator 45.58 19.48

Price Performance

Historical Comparison
SUNS
VRCA

About SUNS Sunrise Realty Trust Inc.

Sunrise Realty Trust Inc is a real estate investment trust company. It is focus on originating CRE debt investments and providing capital to high-quality borrowers and sponsors with transitional business plans collateralized by CRE assets with opportunities for near-term value creation, as well as recapitalization opportunities. It intends to create a diversified investment portfolio, targeting investments in senior mortgage loans, mezzanine loans, whole loans, B-notes, CMBS, and debt-like preferred equity securities across CRE asset classes and investment mix to include high-quality multi-family, condominiums, retail, office, hospitality, industrial, mixed-use, and specialty-use real estate. The company's portfolio is concentrated in the Southern U.S.

About VRCA Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.

Share on Social Networks: